News Sentiment

CLLS sentiment intelligence

Cellectis SA news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.99 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

75/100 classification confidence.

Company focus 38

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-9.4% over one week, -3.2% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

ETFs Investing in Cellectis S.A. Sponsored ADR Stocks

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 75/100 classification
One-week reaction -9.4% Price reacting lower
Trend fit Trend inactive -3.2% over four weeks
Fair value 15.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 35
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 38
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Stock Titan 7
Market source 6
MarketBeat 3
GlobeNewswire 2
simplywall.st 2
The Globe and Mail 1
Barchart 1

Event Lens

What the news is about

Classified themes
Earnings 22
Market update 19
Analyst action 3
Balance sheet 1
Regulatory and legal 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 47
TradingView Direct company coverage

ETFs Investing in Cellectis S.A. Sponsored ADR Stocks

This article lists ETFs that include Cellectis S.A. Sponsored ADR stocks. It highlights the iShares Biotechnology ETF (IBB) as one such fund, providing its market value, weight, issuer, expense ratio, AUM, price, change, related volume, and 3-year NAV total return. The informatio

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 21:39
Source
TradingView
Barchart Direct company coverage

Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics

DelveInsight's "Multiple Myeloma Pipeline Insight, 2026" report highlights the extensive global effort to develop new therapies for Multiple Myeloma, with over 75 companies and 80+ treatments in various stages of development. Recent clinical trial advancements emphasize the effic

Tone
Positive 74/100
Event
Market update
Published
08 Jul 2026 01:10
Source
Barchart
TradingView Direct company coverage

Price to book forward of Cellectis S.A. – EURONEXT:ALCLS

This article provides the "Price to book forward" for Cellectis S.A. (Euronext: ALCLS). It indicates the financial metric for the company, accessible through TradingView's platform, and details the data sources for market and reference information. The content itself seems to be

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 00:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Cellectis S.A. – EURONEXT:ALCLS

This article focuses on the enterprise value to revenue forward for Cellectis S.A. (Euronext: ALCLS). The content, likely a financial data point or an analysis snippet, is presented within the context of TradingView's financial market platform.

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 14:10
Source
TradingView
TradingView Direct company coverage

Price to book forward of Cellectis S.A. – NASDAQ:CLLS

This page provides financial information for Cellectis S.A. (NASDAQ: CLLS), specifically its price-to-book forward ratio. It briefly touches on the company's market data but does not include further details like the actual value or changes in the price-to-book ratio. The content

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 08:40
Source
TradingView
Stock Titan Direct company coverage

Cellectis monthly capital update shows 100.7M shares, 105.6M votes

Cellectis (CLLS) released its monthly capital update for June 30, 2026, reporting 100,698,158 shares outstanding and 105,551,650 voting rights on Euronext Growth. This update provides transparency on the company's capital structure, as required by the French financial markets aut

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:40
Source
Stock Titan
Finimize Direct company coverage

European ADRs Jumped As Biotech Led The Pack

European ADRs, representing foreign shares traded in the US, experienced a significant jump led by biotech companies. The S&P Europe Select ADR Index rose 2.21%, with Cellectis climbing 14% and BioNTech gaining 4.5%. This rise in ADRs can act as a "preview" for European markets w

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 15:40
Source
Finimize
TradingView Direct company coverage

Cellectis S.A. Sponsored ADR Financial Disclosures & SEC Filings

This page provides an extensive list of financial disclosures and SEC filings for Cellectis S.A. (CLLS), including earning reports, corporate presentations, and annual reports dating back to 2022. It highlights key events such as clinical trial progress for UCART22, cash runway u

Tone
Positive 67/100
Event
Balance sheet
Published
01 Jul 2026 21:12
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Cellectis S.A. – EURONEXT:ALCLS

This article displays the "Price to earnings forward" metric for Cellectis S.A. (Euronext:ALCLS) on the TradingView platform. The content is primarily a data placeholder within a financial information service, showing the company's ticker, market status, and indicating that the s

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 23:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Cellectis S.A. – EURONEXT:ALCLS

This article provides a brief mention of the "Price to sales forward" for Cellectis S.A. (EURONEXT:ALCLS) on the TradingView platform. It appears to be a stub or a section of a larger financial data presentation, indicating the availability of this specific financial metric. The

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 17:42
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Cellectis S.A. – FWB:ZVA

This article provides the "Price to earnings forward" value for Cellectis S.A. (FWB:ZVA) on the Frankfurt Stock Exchange. It indicates that no trades have occurred and the market is closed. The content primarily focuses on financial data for this specific company.

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 04:40
Source
TradingView
TradingView Direct company coverage

Cellectis S.A. Actuals & Estimates (EURONEXT:ALCLS)

This article provides comprehensive financial data and analyst estimates for Cellectis S.A. (ALCLS) on EURONEXT. It details current stock performance, historical highs and lows, market capitalization, volatility, and future price forecasts from analysts. The report also includes

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 20:09
Source
TradingView
Stock Titan Direct company coverage

Shareholders of Cellectis (NASDAQ: CLLS) reject savings plan issue

Cellectis S.A. filed an amended Form 6-K to correct a clerical error regarding its Combined General Meeting of Shareholders on June 25, 2026. The amendment clarifies that Resolution 30, which dealt with delegating authority to increase share capital for an employee savings plan,

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:09
Source
Stock Titan
TradingView Direct company coverage

ZVA Forecast — Price Target — Prediction for 2027

This article provides a forecast for Cellectis S.A. (ZVA) stock, including analyst price targets, future earnings estimates, and historical price data. It details the company's financial metrics such as recent earnings per share, revenue, and net income, alongside its EBITDA and

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 15:41
Source
TradingView
TradingView Direct company coverage

Cellectis S.A. Sponsored ADR Actuals & Estimates (NASDAQ:CLLS)

This article provides an overview of Cellectis S.A. (NASDAQ:CLLS) financial actuals and estimates as presented on TradingView. It highlights different financial statements like the income statement, balance sheet, and cash flow, allowing users to compare actual results with analy

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 11:41
Source
TradingView
GlobeNewswire Direct company coverage

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

Cellectis held its shareholders general meeting on June 25, 2026, where resolutions 1 through 29 were adopted, and resolution 30 was rejected. Approximately 55.84% of voting rights were exercised, and the detailed results are available on the company's website. Cellectis is a cli

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 08:41
Source
GlobeNewswire
Stock Titan Direct company coverage

Cellectis (CLLS) meeting backs capital issuance mandates but rejects employee savings share plan

Cellectis S.A. held its Combined General Meeting of Shareholders on June 25, 2026, where key financial items and capital increase delegations, including an “at-the-market” equity financing program on the U.S. market, were approved with strong shareholder support. Shareholders als

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 20:41
Source
Stock Titan
Stock Titan Direct company coverage

[6-K] Cellectis S.A. Current Report (Foreign Issuer) | CLLS SEC Filing - Form 6-K

Cellectis S.A. filed a Form 6-K reporting the results of its shareholders' general meeting held on June 25, 2026. The company announced that resolutions 1 through 29 were adopted, while resolution 30 was rejected, aligning with the board of directors' recommendations. Approximate

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 20:41
Source
Stock Titan
TradingKey Direct company coverage

Cellectis SA (CLLS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Cellectis SA (CLLS), highlighting its current earnings forecast score, average price target from analysts, and expected revenue for the next quarter. It details analyst ratings, revealing a "Buy" trend based on 7 analysts, and includ

Tone
Positive 72/100
Event
Earnings
Published
18 Jun 2026 01:10
Source
TradingKey
MarketBeat Direct company coverage

Cellectis (CLLS) 10K Form and Latest SEC Filings 2026

This article provides an overview of Cellectis (CLLS) SEC filings, including a historical record of documents submitted since 2017. It details the types of filings such as 10-K, 10-Q, and 8-K, explaining their significance for investors. The article notes that Cellectis's most re

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 03:09
Source
MarketBeat
grafa.com Direct company coverage

Cellectis reports strong CAR-T cancer trial data at EHA 2026

Cellectis (NASDAQ:CLLS) presented highly encouraging clinical trial data at the EHA 2026 Congress for its gene-edited, off-the-shelf CAR-T cancer therapies. The company reported a 100% overall response rate for its lead asset, lasme-cel, in a target group of leukemia patients, wi

Tone
Neutral 50/100
Event
Analyst action
Published
11 Jun 2026 12:39
Source
grafa.com
Stock Titan Direct company coverage

Cellectis CAR-T trials show responses in heavily pretreated blood cancers

Cellectis presented final Phase 1 results for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia and preliminary data for eti-cel in relapsed/refractory B-cell non-Hodgkin lymphoma at EHA 2026. Lasme-cel achieved a 100% overall response rate in the target Phase

Tone
Positive 95/100
Event
Earnings
Published
11 Jun 2026 06:39
Source
Stock Titan
Caledonian Record Direct company coverage

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at ...

Cellectis presented final Phase 1 data for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and preliminary data for eti-cel in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) at the EHA 2026 Annual Congress. The lasme-cel trial showed

Tone
Positive 75/100
Event
Earnings
Published
11 Jun 2026 06:39
Source
Caledonian Record
GlobeNewswire Direct company coverage

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

Cellectis presented final Phase 1 data from the BALLI-01 clinical trial for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), showing a 100% overall response rate in the target Phase 2 population. Additionally, preliminary results from the NATHALI-

Tone
Positive 74/100
Event
Earnings
Published
11 Jun 2026 06:39
Source
GlobeNewswire